Strong muscles, weak heart: testosterone‐induced cardiomyopathy

Abstract

Exogenous anabolic androgen steroid use is associated with adverse cardiovascular outcomes. A 53‐year‐old bodybuilder presented with 3 months of exertional dyspnoea. Physical examination showed tachycardia and pan‐systolic murmur; an echocardiogram showed a left ventricular ejection fraction (EF) of 15%. Evaluations included normal coronary angiogram, iron panel and thyroid studies, a negative viral panel (human immunodeficiency virus, Lyme disease, and hepatitis), and urine toxicology. He admitted to intramuscular anabolic steroid use; his testosterone level was 30 160.0 ng/dL (normal 280–1100 ng/dL). In addition to discontinuation of anabolic steroid use, he was treated with guideline‐directed heart failure medical therapy. Repeat echocardiogram at 6 months showed an EF of 54% and normalized testosterone level of 603.7 ng/dL. Anabolic steroid use is a rare, reversible cause of cardiomyopathy in young, otherwise healthy athletes; a high index of suspicion is required to prevent potentially fatal side effects.

Point-of-care Echocardiogram as the Key to Rapid Diagnosis of a Unique Presentation of Dyspnea: A Case Report

“…Although the etiology of this patient's cardiomyopathy was not clearly identified, risk factors seem to be moderate alcohol use and testosterone supplementation, which has been noted to be a potential impetus for cardiomyopathy. 7 POCUS was the key to a quick diagnosis in this protracted case of dyspnea. Thus, POCUS should be an essential part of the ED workup for a patient with dyspnea, regardless of patient age or comorbidities.…”

“…Although the etiology of this patient’s cardiomyopathy was not clearly identified, risk factors seem to be moderate alcohol use and testosterone supplementation, which has been noted to be a potential impetus for cardiomyopathy. 7 …”

A sentinel population: The public health benefits of monitoring enhanced body builders

“…As we enter the 2020s, we have increasing data to evidence the long-term effects of AAS use. The potential for cardiac damage highlighted during the 1980s and 1990s (Mochizuki and Richter 1988, Herschman 1990, Hartgens, Kuipers et al 1996 has been realised in the form of increased case reports (Baggish, Weiner et al 2017, Doleeb, Kratz et al 2019) and analyses of post mortem data (Sculthorpe, Grace et al 2010, Montisci, El Mazloum et al 2012, Pope, Wood et al 2014).…”

Heart failure in the last year: progress and perspective

“…Among the specific causes of HF, cardiomyopathies are a heterogeneous group of heart muscle diseases 23–26 . Current knowledge regarding the incidence and prevalence of cardiomyopathies and HF has been summarized in a recent position paper by the HFA of the European Society of Cardiology (ESC) 27 .…”